FUNDAMENTALS · Fundamentals · US Healthcare

Humana (HUM) Fundamentals 2026 — P/E 42.3x, Revenue Analysis | SniperIQ

Humana (HUM) is a US-listed Healthcare company in Medical - Healthcare Plans with a market capitalization of $47.7B, trading at

96.90 on the NYSE. This SniperIQ fundamentals page covers Humana's valuation (P/E 42.3x, P/B 2.6x), profitability (net margin 0.8%), revenue (
29.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$47.7B
P/E (TTM)42.3x
Net Margin0.8%
Revenue (FY25)
29.7B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Humana's market cap?

Humana (HUM) has a market capitalization of approximately $47.7B, trading at

96.90 on the NYSE. Market cap moves with the live share price.

What is Humana's P/E ratio?

Humana's trailing twelve-month P/E ratio is 42.3x, with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Humana?

Humana runs a net profit margin of 0.8%, a gross margin of 14.0%, and an operating margin of 1.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Humana generate?

Humana reported revenue of

29.7B for fiscal year 2025, with net income of
.2B and earnings per share (EPS) of 9.87. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Humana pay a dividend?

Humana offers a trailing dividend yield of about 0.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Humana financially healthy?

Humana carries a debt-to-equity ratio of 0.75x and a current ratio of 1.26x, with a market beta of 0.72. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Humana a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Humana (HUM) the key facts are: market cap $47.7B, P/E 42.3x, revenue

29.7B, 52-week range 163.11-428.88. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Humana's full fundamentals live

Get Humana's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.